Kodiak’s two retinal treatments meet pivotal trial endpoints
Kodiak Sciences ($KOD) reported that Zenkuda and tabirafusp-ted met their primary vision endpoints in the Phase 3 DAYBREAK trial in wet age-related macular degeneration. Both achieved non-inferior vision gains against aflibercept at one year. Under the study’s stringent retinal-fluid retreatment criteria, 54% of Zenkuda patients reached a six-month dosing interval. Reported intraocular inflammation was 0% with Zenkuda and 0.4% with tabirafusp-ted. The results strengthen the evidence supporting K
0